Pharmaceutical Administration and Regulations in Japan - Nihs
Pharmaceutical Administration and Regulations in Japan - Nihs
Pharmaceutical Administration and Regulations in Japan - Nihs
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
PFSB dated October 1, 2008 <strong>and</strong><br />
Office Communication dated April<br />
2, 2009).<br />
• The director of the medical<br />
<strong>in</strong>stitution perform<strong>in</strong>g the study<br />
must heed the op<strong>in</strong>ions of the IRB<br />
concern<strong>in</strong>g whether it is<br />
appropriate or not to perform the<br />
cl<strong>in</strong>ical study <strong>in</strong> the medical<br />
<strong>in</strong>stitution concerned.<br />
• The medical <strong>in</strong>stitution is not<br />
allowed to conduct a cl<strong>in</strong>ical trial<br />
when the op<strong>in</strong>ion of the IRB is that<br />
it is not appropriate to conduct the<br />
trial.<br />
• When it is impracticable to<br />
organize an IRB for a planned trial<br />
at each <strong>in</strong>stitution, alternative IRB<br />
may be selected from other IRBs<br />
<strong>in</strong>side or outside the <strong>in</strong>stitution <strong>in</strong><br />
the judgment of the director of<br />
medical <strong>in</strong>stitution.<br />
• IRB may disclose <strong>in</strong>formation<br />
related to IRB review to enhance<br />
the level of transparency <strong>and</strong><br />
secure quality of its review<br />
activities.<br />
2) Provisions related to medical<br />
<strong>in</strong>stitutions perform<strong>in</strong>g cl<strong>in</strong>ical trials<br />
(Articles 35 to 41)<br />
• Medical <strong>in</strong>stitutions perform<strong>in</strong>g<br />
cl<strong>in</strong>ical trials must have the<br />
facilities <strong>and</strong> personnel to<br />
<strong>Pharmaceutical</strong> <strong>Regulations</strong> <strong>in</strong> <strong>Japan</strong>:<br />
undertake adequate cl<strong>in</strong>ical<br />
observations <strong>and</strong> laboratory<br />
test<strong>in</strong>g, <strong>and</strong> they must be able to<br />
take the measures required when<br />
emergencies arise among the trial<br />
subjects.<br />
• The director of the medical<br />
<strong>in</strong>stitution perform<strong>in</strong>g the trial must<br />
prepare SOP for work related to<br />
the trial, <strong>and</strong> take the necessary<br />
measures so that the cl<strong>in</strong>ical trial<br />
is conducted properly <strong>and</strong><br />
smoothly <strong>in</strong> compliance with the<br />
trial protocol <strong>and</strong> the SOP.<br />
• The director of the medical<br />
<strong>in</strong>stitution perform<strong>in</strong>g the trial must<br />
cooperate with monitor<strong>in</strong>g or<br />
audits by the sponsor or the<br />
person conduct<strong>in</strong>g the cl<strong>in</strong>ical trial<br />
<strong>and</strong> review by the IRB.<br />
• The director of a medical<br />
<strong>in</strong>stitution must appo<strong>in</strong>t a person<br />
or persons to carry out trial-related<br />
clerical work.<br />
3) Provisions related to <strong>in</strong>vestigators<br />
(Articles 42 to 49)<br />
• The <strong>in</strong>vestigator must have<br />
sufficient cl<strong>in</strong>ical experience to be<br />
able to conduct the trial properly.<br />
• The <strong>in</strong>vestigator must select the<br />
trial subjects <strong>in</strong> accordance with<br />
the objectives of the trial from the<br />
ethical <strong>and</strong> scientific st<strong>and</strong>po<strong>in</strong>ts.<br />
2011-3 - 104 -